# Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b

> **NCT00942591** · PHASE2 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 77 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Interferon beta 1b
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT00942591
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2009-04
- **Final completion:** 2009-05
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2009-07-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00942591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00942591, "Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00942591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*